利莫那班衍生物对高脂肥胖模型小鼠的减肥作用

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (1011 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract]Objective: To investigate the mechanism of analogues of rimonabant ZH-101-S loseweight effect on highfat dietinduced obese mice. Methods: Male ICR mice were fed with high fat diet to build the obese mice model and the mice were divided into control group,obese model group,rimonabant group(30 mg/kg)and ZH-101-S group(15 mg/kg, 30 mg/kg).All drug were administered by intragastric administration per day for 18 days. Body weight and the content/morphology of genital peripheral adipose tissue and morphology of liver were detected, the content of total cholesterol,triacylglycerol,high density lipoprotein cholesterol(HDL-C), glucose, low density lipoprotein cholesterol(LDLC), glutamicoxalacetic transaminase(AST), glutamic-pyruvic transaminase(ALT) and lactic dehydrogenase(LDH) in serum were also estimated. Results: After treated with ZH101-S for 18 days, the bodyweight of mice and the content of genital peripheral adipose tissue were significantly reduced, compared with model group. ZH101-S could decrease the level of triacylglycerol,total cholesterol,LDL-C, LDH in serum and elevate the level of HDLC. Finally, ZH101S protected high fat food induced hepatic injury proved by AST and ALT decrease and improvement of liver morphology. Conclusion: ZH101S could reduce the bodyweight, improve plasma lipid profile and hepatic injury of highfat dietinduced obese mice.

Received: 03 November 2015

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2016/V26/I02/119

\[1\]Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets\[J\]. Mol Cell Endocrinol, 2008, 286(1/2 Suppl 1): S66-S78.
\[2\]Adan RA. Mechanisms underlying current and future antiobesity drugs\[J\]. Trends Neurosci, 2013, 36(2): 133-140.
\[3\]Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistatassociated adverse effects and drug interactions\[J\]. Drug Saf, 2008, 31(1): 53-65.
\[4\]George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity\[J\]. J Cardiovasc Pharmacol Ther, 2014, 19(1): 65-76.
\[5\]Thomas BF, Francisco ME, Seltzman HH, et al. Synthesis of longchain amide analogs of the cannabinoid CB1 receptor antagonist N(piperidinyl)5(4chlorophenyl)1(2，4dichlorophenyl)4methyl1Hpyrazole3carboxamide(SR141716) with unique binding selectivities and pharmacological activities\[J\]. Bioorg Med Chem, 2005, 13(18): 5463-5474.
\[6\]Leite CE, Mocelin CA, Petersen GO, et al. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity\[J\]. Pharmacol Rep, 2009, 61(2): 217-224.
\[7\]GaryBobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesityassociated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats\[J\]. Hepatology, 2007, 46(1): 122-129.
\[8\]Van Gaal LF,Rissanen AM,Scheen AJ, et al. Effects of the cannabinoid1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients：1year experience from the RIOEurope Study\[J\]. Lancet, 2005, 365(9468): 1389-1397.
\[9\]Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia \[J\]. N Engl J Med, 2005, 353(20): 2121-2134.
\[10\]Jones D. End of the line for cannabinoid receptor 1 as an antiobesity target \[J\]. Nat Rev Drug Discov, 2008, 7(12): 961-962.
\[11\]Takano A, Gulyas B, Varnas K, et al. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study\[J\]. Synapse, 2014, 6(83): 89-97.
\[12\]Starowiicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a highfat diet\[J\]. Obesity, 2008, 16(3): 553-565.
\[13\]Staehr P, HotherNielsen O, BeckNielsen H, et al. The role of the liver in type 2 diabetes\[J\]. Rev Endocr Metab Disord, 2004, 5(2): 105-110.
\[14\]杨海冬, 高静, 李静, 等. 利莫那班改构物对高脂饮食诱导肥胖小鼠的减肥效应及机制\[J\]. 江苏大学学报: 医学版, 2012, 22(3): 231-235.